Cell-based immunotherapy such as ALECSAT is well tolerated and have very few side effects as demonstrated in all clinical programs.
ALECSAT has specificity for and recognizes different cancer-specific antigens.
ALECSAT will also be efficacious in patients with inhibited immune defense mechanisms.
ALECSAT has three potential modes of actions: